The current investigation examined the early MEM treatment for its anti-AD effect, as well as its preconditioning anti-stroke effect, in the GluN3A KO mouse as a sporadic AD model, and the 5xFAD mouse as a human amyloid pathology model. Here, GRIN3A is linked to stroke disorder.